The stock is a binary event driven by mid-2026 SIGNAL-AA data. The extended cash runway into 1H 2028 removes near-term financing risk, but the $75M ATM filed 11 days ago adds overhang. Monitor for any early data disclosures or analyst days ahead of the topline readout.
Price Chart
Executive Summary
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D and G&A expenses. Cash runway extended into 1H 2028 following a $10.5M RDO and $14.2M ATM proceeds, with the key catalyst being mid-2026 topline data from the SIGNAL-AA Phase 2a trial for bempikibart. The sequential improvement in cash burn and extended runway are positive, but the stock remains a binary event driven by clinical data.
Key Financial Metrics
Key Facts
- Net loss narrowed to $7.6M ($0.54/share) in Q1 2026 from $11.0M ($0.90/share) in Q1 2025
- Cash and cash equivalents of $50.8M as of March 31, 2026, plus $14.2M in ATM proceeds received after quarter-end
- Cash runway extended into first half of 2028, from prior guidance of Q4 2027
- Bempikibart 36-week topline data from Part B of SIGNAL-AA Phase 2a trial on track for mid-2026
- First patient dosed in Part B open-label extension (OLE)
- R&D expenses fell to $3.2M from $7.1M YoY due to reduced headcount and lower clinical spend
- G&A expenses fell to $4.5M from $5.1M YoY due to lower legal and consulting costs
- ATM program raised $14.2M in gross proceeds after quarter-end; $75M ATM filed April 24, 2026
Financial Impact
Net loss improved by $3.4M YoY; cash position increased $2.5M sequentially; $24.7M in total capital raised (RDO + ATM) in Q1 2026
Risk Factors
- Phase 2a topline data may fail to meet efficacy endpoints, causing significant downside
- ATM overhang of up to $75M could pressure stock price regardless of clinical outcomes
- Pre-revenue biotech with no approved products; any clinical setback could threaten viability
- Small open-label trial (33 patients) limits statistical robustness of efficacy signals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-205006 |
| Document: qttb-20260505.htm | 0001193125-26-205006 |
| Document: 0001193125-26-205006-index-headers.html | 0001193125-26-205006 |
| Document: 0001193125-26-205006-index.html | 0001193125-26-205006 |
| Document: 0001193125-26-205006.txt | 0001193125-26-205006 |
| 8-K Data (Synthetic) | 0001193125-26-205006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.23 (−24.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.23 (−49.04%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.23 (−50.09%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.23 (+47.58%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.23 (−55.42%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.23 (−37.51%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.23 (−34.89%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.23 (+60.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access